Effect of SSRIs on Response to Psilocybin Therapy

Summary

This study is an open-label, single-arm, within-subjects design in individuals with mild-moderate Major Depressive Disorder (MDD). All participants will receive a single dose of 25mg of psilocybin in a therapeutic setting. In order to investigate the effects of length of time on SSRI therapy, 30 participants with varying lengths of time on SSRI therapy will be enrolled, stratified into four groups: * Group 1: ≤ 1 year * Group 2: 1 to ≤ 5 years * Group 3: 5 to ≤ 10 years * Group 4: \> 10 years

Timeline

Start

2023-01-01

Primary completion

2023-03-14

Completion

2023-03-14

Outcome

Outcome not reported

Stopped (Business): “Funding”

Drugs

Indications